Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 7/20 | 0.78 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.78 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.78 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.78 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.78 |
| ▸ | DRD1 | P21728 | 1/20 | 0.78 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.78 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.78 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.78 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.78 |
| ▸ | DRD3 | P35462 | 1/20 | 0.78 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.78 |
| ▸ | DRD2 | P14416 | 5/20 | 0.56 |
| ▸ | HTR2A | P28223 | 2/20 | 0.56 |
| ▸ | HTR7 | P34969 | 4/20 | 0.54 |
| ▸ | HTR2C | P28335 | 2/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.52 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | TP53 | P04637 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6605767 | 0.92 | HTR1A (0.78) | HTR1AABCB11ADRA2AADORA3CHRM1 | |
| Flibanserin SCHEMBL29399513 | 0.88 | HTR1A (1.00) | HTR1AABCB11ADRA2AADORA3CHRM1 | |
| Flibanserin SCHEMBL30249132 | 0.88 | HTR1A (1.00) | HTR1AABCB11ADRA2AADORA3CHRM1 | |
| Flibanserin SCHEMBL247579 | 0.88 | HTR1A (1.00) | HTR1AABCB11ADRA2AADORA3CHRM1 | |
| Flibanserin SCHEMBL563586 | 0.87 | HTR1A (0.98) | HTR1AABCB11ADRA2AADORA3CHRM1 | |
| Flibanserin SCHEMBL19743151 | 0.87 | HTR1A (0.98) | HTR1AABCB11ADRA2AADORA3CHRM1 | |
| Flibanserin SCHEMBL2526226 | 0.87 | HTR1A (0.98) | HTR1AABCB11ADRA2AADORA3CHRM1 | |
| Flibanserin SCHEMBL19743166 | 0.87 | HTR1A (0.98) | HTR1AABCB11ADRA2AADORA3CHRM1 | |
| SCHEMBL12744407 | 0.86 | HTR1A (0.57) | HTR1AABCB11ADRA2AADORA3CHRM1 | |
| SCHEMBL14530493 | 0.86 | HTR7 (0.66) | HTR1AABCB11ADRA2AADORA3CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1218352-A1 | BENZIMIDAZOLONE DERIVATIVES HAVING MIXED SEROTONINE AND DOPAMINE RECEPTORS AFFINITY | BOEHRINGER INGELHEIM ITALIA S.p.A. (IT) | 2002-07-03 | — | — | EP | claimed |
| US-6281218-B1 | USEFUL IN THE TREATMENT OF CNS DISORDERS. | INGELHEIM ITALIA S.P.A. (IT) | 2001-08-28 | — | — | US | claimed |
| WO-2001021593-A1 | NEW BENZIMIDAZOLONE DERIVATIVES HAVING MIXED SEROTONINE AND DOPAMINE RECEPTORS AFFINITY | BOEHRINGER INGELHEIM ITALIA S.P.A. (IT) | 2001-03-29 | — | — | WO | claimed |
| US-20150368204-A1 | Sulfated Benzimidazolone Derivatives Having Mixed Serotonine Receptor Affinity | Salix Pharmaceuticals, Ltd | 2015-12-24 | — | — | US | disclosed |
| US-20150011564-A1 | Sulfated Benzimidazolone Derivatives Having Mixed Serotonine Receptor Affinity | SPROUT PHARMACEUTICALS, INC. (US) | 2015-01-08 | — | — | US | disclosed |
| US-8722682-B2 | Sulfated benzimidazolone derivatives having mixed serotonin receptor affinity | SPROUT PHARMACEUTICALS, INC. (US) | 2014-05-13 | — | — | US | disclosed |
| EP-2097389-B1 | SULFATED BENZIMIDAZOLONE DERIVATIVES HAVING MIXED SEROTONINE RECEPTOR AFFINITY | BOEHRINGER INGELHEIM INT (DE) | 2011-09-14 | — | — | EP | disclosed |
| US-7923449-B2 | Using 1-(2-(3-trifluoromethylphenyl)piperazin-1-yl)ethyl)2,3-dihydro-1H-benzimidazol-2-one | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-04-12 | — | — | US | disclosed |
| US-7923449-B2 | Using 1-(2-(3-trifluoromethylphenyl)piperazin-1-yl)ethyl)2,3-dihydro-1H-benzimidazol-2-one | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-04-12 | — | — | US | disclosed |
| US-20110015207-A1 | SULFATED BENZIMIDAZOLONE DERIVATIVES HAVING MIXED SEROTONINE RECEPTOR AFFINITY | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-01-20 | — | — | US | disclosed |
| US-20090176698-A1 | Benzimidazolone Derivatives for the Treatment of Urinary Incontinence | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-07-09 | — | — | US | disclosed |
| US-20080242679-A1 | Benzimidazolone Derivatives For the Treatment of Premenstrual and Other Female Sexual Disorders | VRX HOLDCO LLC | 2008-10-02 | — | — | US | disclosed |
| WO-2008061968-A1 | BENZIMIDAZOLONE DERIVATES IN THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-05-29 | — | — | WO | disclosed |
| WO-2007096300-A1 | BENZIMIDAZOLONE DERIVATIVES FOR THE TREATMENT OF URINARY INCONTINENCE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-08-30 | — | — | WO | disclosed |
| US-20070123540-A1 | Sexual desire enhancing medicaments comprising benzimidazolone derivatives | CECI ANGELO | 2007-05-31 | — | — | US | disclosed |
| US-20070123540-A1 | Sexual desire enhancing medicaments comprising benzimidazolone derivatives | CECI ANGELO | 2007-05-31 | — | — | US | disclosed |
| WO-2007048803-A1 | BENZIMIDAZOLONE DERIVATIVES FOR THE TREATMENT OF PREMENSTRUAL AND OTHER FEMALE SEXUAL DISORDERS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-05-03 | — | — | WO | disclosed |
| EP-1218352-A1 | BENZIMIDAZOLONE DERIVATIVES HAVING MIXED SEROTONINE AND DOPAMINE RECEPTORS AFFINITY | BOEHRINGER INGELHEIM ITALIA S.p.A. (IT) | 2002-07-03 | — | — | EP | disclosed |
| US-6281218-B1 | USEFUL IN THE TREATMENT OF CNS DISORDERS. | INGELHEIM ITALIA S.P.A. (IT) | 2001-08-28 | — | — | US | disclosed |
| WO-2001021593-A1 | NEW BENZIMIDAZOLONE DERIVATIVES HAVING MIXED SEROTONINE AND DOPAMINE RECEPTORS AFFINITY | BOEHRINGER INGELHEIM ITALIA S.P.A. (IT) | 2001-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070123540-A1 | Sexual desire enhancing medicaments comprising benzimidazolone derivatives | SHBG, GABBR1, GABRE | HTR1A 78/4885ABCB11 1608/4885ADRA2A 85/4885 |
| US-20090176698-A1 | Benzimidazolone Derivatives for the Treatment of Urinary Incontinence | HRH2, AVPR2, HRH1 | HTR1A 765/4885ABCB11 868/4885ADRA2A 296/4885 |
| US-20150011564-A1 | Sulfated Benzimidazolone Derivatives Having Mixed Serotonine Receptor Affinity | HTR3B, HTR3A, HTR1E | HTR1A 4/4885ABCB11 794/4885ADRA2A 292/4885 |
| US-20150368204-A1 | Sulfated Benzimidazolone Derivatives Having Mixed Serotonine Receptor Affinity | HTR3B, HTR3A, HTR1E | HTR1A 4/4885ABCB11 849/4885ADRA2A 288/4885 |
| US-20080242679-A1 | Benzimidazolone Derivatives For the Treatment of Premenstrual and Other Female Sexual Disorders | GABBR1, CYP19A1, GABBR2 | HTR1A 195/4885ABCB11 2387/4885ADRA2A 467/4885 |
| US-20110015207-A1 | SULFATED BENZIMIDAZOLONE DERIVATIVES HAVING MIXED SEROTONINE RECEPTOR AFFINITY | HTR3A, HTR3B, NPSR1 | HTR1A 7/4885ABCB11 725/4885ADRA2A 192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.